Trial Profile
A double-blind, double-dummy, dose-ranging study evaluating Oral, Direct Factor Xa Inhibitor, BAY 59-7939 [rivaroxaban] for the prevention of venous thromboembolism after total hip replacement (ODIXa-HIP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Enoxaparin sodium
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms ODIXa-HIP